Amesite Inc. (NASDAQ: AMST) entered into definitive agreements for a registered direct offering and a private placement of 696,866 shares of its common stock at a purchase price of $1.435 per share, a price that reflects the company’s current market value under Nasdaq rules. The offering is priced at‑the‑market and is expected to close on or about April 28, 2026, subject to customary closing conditions.
The equity raise comes as Amesite reports a sharp decline in revenue and a widening loss. Fiscal year 2025 revenue fell 33.81% to $110,459, and the company posted a net loss of $3.62 million. In Q2 2026 the loss per share was $0.16, an improvement from $0.40 in Q2 2025, but the company remains in a cash‑burn cycle that has triggered a Nasdaq deficiency letter for failing to meet the minimum stockholders’ equity requirement. The $2 million proceeds are earmarked for general corporate purposes, primarily working capital, to shore up liquidity and avoid a potential delisting.
Amesite’s strategic pivot from an education‑centric model to a healthcare‑focused one has not yet translated into significant commercial traction. The company’s NurseMagic™ platform competes with established players such as Epic and Oracle Cerner, and its revenue base remains small. The lack of market share and the intense competition underscore the urgency of the capital raise, as the company seeks to fund product development and sales expansion while maintaining regulatory compliance.
In addition to the share sale, Amesite will issue unregistered Series A‑1 and Series A‑2 warrants that allow holders to purchase up to 696,866 shares each at an exercise price of $1.435. If fully exercised on a cash basis, the warrants could generate an additional $4 million in gross proceeds, but they also represent a potential dilution to existing shareholders. The combined $6 million in potential proceeds is intended to extend the company’s runway and support its transition into the healthcare sector.
Market reaction to the announcement has been tempered by concerns over the company’s ongoing cash burn, the Nasdaq delisting risk, and the dilutive nature of the equity raise. Investors have focused on the company’s inability to generate positive cash flow, the narrow margin between its operating expenses and revenue, and the lack of a clear path to profitability in a highly competitive market. These factors have reinforced a cautious outlook for the company’s near‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.